NatWest Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

NatWest Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-6,786	Closed	-$545K	–	138
2015 Q3	$545K	Buy	+6,786	New	+$754K	0.01%	268
2015 Q2	–	Sell	-6,786	Closed	-$709K	–	378
2015 Q1	$709K	Buy	6,786 +17	+0.3%	+$1.72K	0.01%	272
2014 Q4	$657K	Buy	+6,769	New	+$627K	0.01%	272

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

NatWest Group's ALNY Position: Q4 2015 in Review

NatWest Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 6,786 shares — an estimated $545K sold.

NatWest Group first reported a position in ALNY in Q4 2014 and held it in 3 quarters. The position peaked at $709K in Q1 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

NatWest Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 6,786 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $545K.
NatWest Group first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 3 quarters.
NatWest Group's Alnylam Pharmaceuticals position peaked at $709K in Q1 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.